Genmab A/S
Officials from Genmab A/S report on recent activities
Published in Medicine and Law Weekly, July 27th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Genmab A/S.
Report 1: Genmab A/S (CSE: GEN) announced that development plans for ofatumumab (HuMax-CD20(R)) will be described at GlaxoSmithKline's (GSK) Oncology Seminar today. Ofatumumab is currently in late stage development for chronic lymphocytic leukemia (CLL), follicular non-Hodgkin's lymphoma (NHL) and in Phase II for rheumatoid arthritis (RA) and is being developed under a worldwide co-development and commercialisation agreement between Genmab and GSK.
A clear...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Cancer
Reports from University of Sheffield, Department of Psychology add new data to research in cancer in children - Cancer Therapy
New findings reported from Seoul National University, Department of Internal Medicine describe advances in cancer therapy - Craniocerebral Trauma
Reports from Barrow Neurological Institute add new data to research in craniocerebral trauma - Diabetes Risk Factors
Researchers from University of Liege, Department of Medicine report details of new studies and findings in the area of diabetes risk factors - Epidemiology
Studies conducted at Loma Linda University on epidemiology recently published - Health Policy
Recent findings from Queensland University of Technology, Institute for Health highlight research in health policy - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
